Design Therapeutics, Inc. (DSGN) earnings
DSGN earnings moved a median of +4.57% by the close. Quarterly and annual DSGN reports and results, each read against the price at its own news timestamp. Back to the DSGN overview →
21 measured DSGN earnings events.
Where these DSGN earnings landedvs 21 measured DSGN earnings reactions
| Middle 50% of DSGN earnings reactions | +0.21% to +6.67% |
|---|---|
| Median reaction (to close) | +4.57% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 DSGN earnings events with a measured close landed between +0.21% and +6.67%; 76% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results | Press release | -2.91% | +5.98% | |
| Form 10-Q Design Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -2.91% | +5.98% | |
| Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Press release | +15.69% | +21.46% | |
| Form 10-Q Design Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +15.69% | +21.46% | |
| Form 10-K Design Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.38% | -5.22% | |
| Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results | Press release | +0.00% | +6.68% | |
| Form 10-Q Design Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +6.68% | |
| Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results | Press release | -0.25% | +5.68% | |
| Form 10-Q Design Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.25% | +5.68% | |
| Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results | Press release | +1.51% | +6.67% | |
| Form 10-Q Design Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +1.51% | +6.67% | |
| Form 10-K Design Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.31% | +0.00% | |
| Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio | Press release | +0.00% | +1.04% | |
| Form 10-Q Design Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +1.04% | |
| Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio | Press release | +0.11% | -0.64% | |
| Form 10-Q Design Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.11% | -0.64% | |
| Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones | Press release | -0.38% | +0.21% | |
| Form 10-Q Design Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -0.38% | +0.21% | |
| Form 10-K Design Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -11.34% | -0.34% | |
| Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 | Press release | +0.69% | +4.57% | |
| Form 10-Q Design Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.69% | +4.57% |
Keep exploring
More DSGN: analyst actions → · SEC filings → · DSGN overview →